{"entity":{"id":"nct06111274","kind":"trial","name":"A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of Pimicotinib (ABSK021) in pancreatic ductal adenocarcinoma, run by Abbisko Therapeutics Co, Ltd, now recruiting.","summary":"A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer is a phase 2 interventional study registered as NCT06111274 by Abbisko Therapeutics Co, Ltd, with 82 participants planned, started 2023-10-17 and due to reach its primary completion in 2025-12-30. Interventions recorded: Pimicotinib (ABSK021).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06111274","url":"https://clinicaltrials.gov/study/NCT06111274"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["abbisko"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06111274","phase":"2","setting":"A Multicenter, Open-Label Phase II Study To Evaluate The Efficacy And Safety Of ABSK021 In Combination With Chemotherapy With Or Without Toripalimab In Patients With Advanced Pancreatic Cancer","sponsor":"Abbisko Therapeutics Co, Ltd","enrolled":82,"outcomes":[]},"route":"/trials/nct06111274/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","route":"/companies/abbisko/"}]}}